Pentracor is a medical technology company that has developed a groundbreaking innovation to treat acute myocardial infarction. Our first product on the German market is PentraSorb® CRP and has attracted a lot of attention since the conclusion of a groundbreaking clinical trial. Pentracor has a research and development pipeline in several therapeutic areas based on our unique expertise in immunology.
In the case of heart attack and stroke, the C-reactive protein (CRP) leads to an increase in primary damage. Also in the case of diseases of the rheumatic circle of forms, the severity of the diseases is often determined by the amount of CRP.
The CRP adsorber (PentraSorb® CRP) is CE marked. The corresponding certificate for the quality management system in accordance with EN ISO 13485 and the EC certificate of conformity in accordance with RL 93/42/EEC are available.
In our flyer we have summarized the most important information about the PentraSorb® CRP.